Xaira hires former Roche exec as CMO; 'Tis the season for retirements at...
The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo Fontoura as its chief medical officer and internally promoting co-founder...
View ArticleAbbVie makes another small I&I acquisition, buying Nimble for $200M
In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune startup. The Chicago-area pharma giant is dishing out $200 million...
View ArticleEisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M...
Plus, news about Candel, Inovio and RemeGene: Eisai licenses Newron Pharmaceuticals’ evenamide: Eisai’s subsidiary EA Pharma will pay up to €117 million ($123 million) in upfront and milestone fees for...
View ArticleRepare plans for Phase 3 endometrial cancer study, sidelining ovarian cancer
Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in endometrial cancer and ovarian cancer, respectively, and now plans to take the...
View ArticleSABCS Roundup: BeiGene and Pfizer CDK4 inhibitors, ALX’s CD47
This year’s San Antonio Breast Cancer Conference yielded major clinical updates on some of the hottest areas of oncology, from VEGF bispecifics that hope to challenge Merck’s Keytruda on efficacy to ...
View ArticleBeiGene licenses MAT2A cancer drug, matches with Ideaya’s combo plans
BeiGene said it will take on an early-stage drug for solid tumors with MTAP deletion for $150 million upfront and "time-based payments," in a move that would put it in a contest with Ideaya’s combo ...
View ArticleBoundless shares dip as it nixes cancer asset, reshuffles execs
Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just eight months after debuting on the Nasdaq. The San Diego-based biotech has...
View ArticleEMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not...
The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday but said a label expansion of Eli Lilly's blockbuster diabetes drug Mounjaro...
View ArticleBicycle Therapeutics stock sinks following cancer data
Bicycle Therapeutics shared several batches of data for its bicyclic toxin conjugate in metastatic urothelial cancer, non-small cell lung cancer and breast cancer, but the response rates for the drug...
View ArticleFDA stands by mifepristone safety label in federal court challenge
The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and medically unnecessary.” In response to a lawsuit filed last year by several...
View ArticleMcKinsey fined $650M for deceiving US on opioid consulting
McKinsey has accepted a $650 million fine after admitting that it helped accelerate sales of Purdue Pharma's opioid products and misled the US government about its conflict-of-interest policy, allowing...
View ArticleOrganon's steroid-free cream Vtama wins approval in atopic dermatitis
Organon won a label expansion on Friday for the steroid-free topical cream it picked up from its October acquisition of Dermavant. Vtama, also known as tapinarof, is now approved to treat adults and...
View ArticleFTC OKs Novo-Catalent deal, in major win for Novo Nordisk’s GLP-1 manufacturing
After some delay, the Federal Trade Commission has approved Novo Holdings’ $16.5 billion acquisition of Catalent, a week following the European Commission's go-ahead. Now that both regulatory parties...
View ArticleThe Endpoints 100 is back; Inside Isomorphic Labs; FDA adcomm discusses...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleRoche terminates a Phase 3 Spark gene therapy in hemophilia A
Roche has officially discontinued a Phase 3 hemophilia A gene therapy from its Spark Therapeutics unit, a spokesperson for the Swiss pharma told Endpoints News on Friday afternoon. The drugmaker...
View ArticleBristol Myers drops cell therapy pacts with Immatics, Century as part of...
Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with Century Therapeutics for natural killer cell and T cell-based cancer treatments....
View ArticleNovo Nordisk to spend $1.2B for new rare disease drug factory in Denmark
Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 billion ($1.2 billion) to build a new factory in Denmark to ...
View ArticleBiohaven’s protein degrader cuts antibodies by 60%
Biohaven said the lowest dose of BHV-1300 cut the levels of the autoimmune antibody IgG by more than 60%, according to a new cut of data from an ongoing multiple ascending dose trial. This falls ...
View ArticlePureTech declares mid-stage trial win for pulmonary fibrosis drug
PureTech Health unveiled positive Phase 2b data on Monday for its idiopathic pulmonary fibrosis drug, which showed it can reduce lung function decline in patients. The drug hit the trial's primary ...
View ArticleCandid inks three T cell engager deals; PepGen trial put on hold
Plus, news about Foghorn Therapeutics, Incyte, BioNTech, Galderma, Basilea, Innovia, Pharming, bit.bio, Promise Bio, Outlook Therapeutics and Trevi Therapeutics: Candid Therapeutics’ trio of T cell...
View Article